Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS

Are you working with therapeutic peptides such as GLP-1 analogues and looking for more powerful characterisation tools to support your development pipeline or regulatory submissions?

GLP 1 analogues are complex molecules, and generating the analytical insight needed to support development and regulatory submissions can be challenging.

Regulatory agencies expect comprehensive analytical characterisation of therapeutic peptides, including peptide structure, purity, impurities and stability. For GLP 1 analogues, this is particularly challenging because these molecules can be susceptible to chemical and conformational change, and many include structural modifications that increase analytical complexity compared with traditional small molecules.

Join us for a focused webinar on how cyclic ion mobility spectrometry (cyclic IMS) is enabling exactly that level of insight with the resolution and confidence required for both R&D and submission-ready data packages.

What you will learn

• Why cyclic IMS outperforms conventional ion mobility for peptide analysis
• Characterising GLP-1 and related therapeutics: conformers, isomers, and beyond
• Building a robust analytical framework to meet FDA and EMA expectations

Can't attend the webinars live? Register today and watch the episodes on-demand at your convenience.

Speaker: Dale Cooper-Shepherd (Principal Consulting Scientist, Waters Corporation, UK)

Dale Cooper Shepard specialises in ion mobility‑mass spectrometry, with particular expertise in cyclic IMS. His work focuses on applying advanced separation techniques to improve resolution of complex mixtures and enable deeper structural insights, supporting challenging analyses in areas such as bioanalysis and pharmaceutical research.

Speaker: Antonia Wierzbicki (Principal MS Market Dev Manager, EMEA, Waters Corporation)

Antonia has BSc in Pharmaceutical Science and a MSc in Cancer Pharmacology.

Following several years working as an analytical chemist in drug development roles within both academic labs and contract research organizations, Antonia has more recently spent time working with analytical chemists to provide solutions using cutting edge technologies to meet their needs and requirements, with a specific interest in ultra-sensitive quantitation of small molecules.

Antonia is based in Cambridge UK and keen to connect with like-minded scientists in the field.